Malhotra 2024 — SURMOUNT-OSA Tirzepatide

New England Journal of Medicine·June 21, 2024

Atul Malhotra, Ronald R. Grunstein, et al.

Summary

Tirzepatide reduced AHI by 51-63% in patients with OSA and obesity. First GLP-1/GIP therapy shown effective for sleep apnea.

Study Details

Study Design

Phase 3 RCT

Indication

Obstructive sleep apnea with obesity

Intervention

Tirzepatide

Species

Human

Sample Size

469 subjects

Risk of Bias Assessment

Lilly-sponsored